Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo

Oncogene
L WhitesellL M Neckers

Abstract

Mutation of the tumor suppressor gene p53 is the most common genetic abnormality detected in human cancers. Wild type p53 is a short-lived protein with very low basal intracellular levels. Most mutated forms of the protein, however, display markedly increased intracellular levels as an essential feature of their positive transforming activity. In this report, we have used selective inhibitors of the 20S proteasome to demonstrate that processing of p53 by ubiquitination and proteasome-mediated degradation is impaired by commonly occuring mutations of the protein. We found that this impairment of p53 turnover can be reversed by treatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction in intracellular p53 levels. Finally, using cells which over-express a mutant p53 protein, we were able to demonstrate that restoration of proteasome-mediated degradation by geldanamycin is accompanied by p53 polyubiquitination. Although much remains to be learned about the mechanisms involved, our data demonstrate that selective de-stabilization of mutant transforming proteins such as p53 can be achieved pharmacologically with agents such as geldanamycin which modify the function of molecular chaperone pr...Continue Reading

Citations

Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Mikhail V Blagosklonny
Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Rochelle BagatellLuke Whitesell
Nov 12, 2005·Journal of Cancer Research and Clinical Oncology·Megumi SenjuEisaburo Sueoka
Feb 20, 2009·Annals of Nuclear Medicine·Tu WenyongHuang Ying
Nov 4, 2000·The Biochemical Journal·T R HuppK L Ball
Dec 2, 2000·Cell Proliferation·K HelmbrechtL Rensing
Feb 19, 2011·The Journal of Biological Chemistry·Gwanghyun JungJoseph P Albanesi
Sep 5, 2001·The EMBO Journal·M ZyliczA Wawrzynow
Jul 23, 2004·Anti-cancer Drugs·Jason Beliakoff, Luke Whitesell
Mar 16, 2002·Cell Stress & Chaperones·Donkena Krishna VanajaCharles Y F Young
Mar 11, 2006·Médecine sciences : M/S·Walid DridiRégen Drouin
Jan 6, 2007·Journal of Neuropathology and Experimental Neurology·Ying GengKevin A Roth
Aug 4, 1998·FEBS Letters·G G MasonA J Rivett
Sep 20, 2011·Cancer Letters·Jason N SterrenbergAdrienne L Edkins
Apr 20, 2007·Biochemical and Biophysical Research Communications·Zhao-Dong LiBing-Hua Jiang
Sep 25, 2004·Journal of Cellular Physiology·Motohiro NomuraDavid Zagzag
Mar 31, 2009·International Journal of Cancer. Journal International Du Cancer·Galya AbrhamUri Nir
Aug 30, 2008·The FEBS Journal·Craig StevensTed R Hupp
Jan 27, 2011·Journal of Cellular Biochemistry·Jia WangQing-long Guo
Aug 16, 2005·Biochemical and Biophysical Research Communications·M NomuraJ Yamashita
Nov 21, 1997·Biochemical and Biophysical Research Communications·T W SchulteL M Neckers
Feb 12, 1999·Molecular Genetics and Metabolism·H J OchelL Neckers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.